[1. Valerianova Z, Dimitrova N, Vukov M, Atanasov E, editors. Cancer incidence in Bulgaria 2013. Sofia: Paradigma; 2015.]Search in Google Scholar
[2. Goldfarb RA, Fan Y, Jarosek S, Elliott SP. The burden of chronic ureteral stenting in cervical cancer survivors. Int Braz J Urol. 2016. doi: 10.1590/S1677-5538.IBJU.2016.0667. [Epub ahead of print] Pub Med PMID: 27649113.]Search in Google Scholar
[3. Goodwin WE, Casey WC,Woolf W. Percutaneous trocar (needle) nephrostomy in hydronephrosis. J Am Med Assoc. 1955;157:891-4.10.1001/jama.1955.02950280015005]Search in Google Scholar
[4. Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral stents inserted cystoscopically. J Urol. 1967;97:840-4.10.1016/S0022-5347(17)63130-6]Search in Google Scholar
[5. Chitale SV, Scott-Barrett S, Ho ET, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. Clin Radiol. 2002;57:1118-21.10.1053/crad.2002.1114]Search in Google Scholar
[6. Lee SK, Jones HW 3 . rd Prognostic significance of ureteral obstruction in primary cervical cancer. Int J Gynecol Obstet. 1994;44:59-65.10.1016/0020-7292(94)90024-8]Search in Google Scholar
[7. Dyer RB, Regan JD, Kavanagh PV, Khatod EG, Chen MY, Zagoria RJ. Percutaneous nephrostomy with extensions of the technique: step by step. Radiographics. 2002;22(3):503-25.10.1148/radiographics.22.3.g02ma1950312006684]Search in Google Scholar
[8. Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction.Ann RColl Surg Engl. 2005;87(1):21-4.10.1308/1478708051432196383015720902]Search in Google Scholar
[9. Romero FR, Broglio M, Pires SR, Roca RF, Guibu IA, Perez MD. Indications for percutaneous nephrostomy in patients with obstructive uropathy due to malignant urogenital neoplasias. Int Braz J Urol. 2005;31(2):117-24. 10.1590/S1677-55382005000200005]Search in Google Scholar